October 20, 2022 – 11 AM EST

Webinar Highlights

You will learn:

  • A strategy for generating recombinant mAbs and antibody derivatives directed towards antigens involved in mitotic cell division
  • Applications of NGPS to aid engineering and recombinant production of antibodies
  • How Next Generation Protein Sequencing (NGPS) works
  • Methods for antibody engineering and customization, species switching, construction of antibody fragments

Abstract

Increasing the Versatility of Recombinant Antibodies Targeting Mitotic Epitopes

Monoclonal antibodies (mAbs) are indispensable reagents across many basic, translational, and biomedical applications from biomolecule detection to protein purification to medical diagnostics and therapeutics. However, traditional mAbs generated in animals have their drawbacks. Concerns regarding traditionally produced mAbs include: reproducibility, incomplete characterization, consistent availability, and cost. In short, good mAbs are hard to find for certain targets and biological processes such as mitosis.

In order to maintain genomic integrity, proper segregation of chromosomes into the two daughter cells must occur. This process is powered and regulated by the kinetochores, which are structures built at the primary constriction of mitotic chromosomes that attach to spindle microtubules. The primary factor connecting the kinetochores to the microtubules is the kinetochore-associated NDC80 complex.

Advancements in protein sequencing techniques have made it possible to acquire the primary amino acid sequence of mAbs that target the NDC80 complex of the mitotic process. The invariant primary sequences were used for downstream construction and production of sequence-defined recombinant mAbs and antibody fragments, including scFvC, scFv, and Fab, all showing robust binding to the kinetochore target in mitotic cells. Moreover, this methodical approach circumvented the issues listed above, providing a straightforward and accessible strategy for generating low-cost, high-yield preparations of recombinant mAbs and antibody fragments.

Speaker Bios

Newsletter for All Things Protein Sequencing

Breakthrough Bispecific Antibody R&D Techniques, Apr 20 11:00am EST.

Talk to Our Scientists.

We Have Sequenced 6000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 6000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 6000 antibodies and we are eager to help you.